Short Bowel Syndrome Market by Drug Class (GLP-2, Glutamine, Growth Hormone), Distribution Channel

List of Tables

The Short Bowel Syndrome Market was valued at USD 818.23 million in 2023, expected to reach USD 966.42 million in 2024, and is projected to grow at a CAGR of 19.14%, to USD 2,788.72 million by 2030.

Short Bowel Syndrome (SBS) is a rare, serious condition characterized by the inability to adequately absorb nutrients due to insufficient functional small intestine. The scope of SBS treatment spans nutritional support, medications, and surgery, highlighting the necessity for efficient solutions in improving patient quality of life. Applications of SBS treatment encompass the use of parenteral nutrition, enteral nutrition, and drugs like teduglutide to enhance absorption. The end-use scope covers hospitals, clinics, and homecare settings, each contributing differently to the market demand. As the global healthcare landscape evolves, key growth factors in the SBS market include advancements in medical nutrition therapy and increasing awareness about rare diseases. The development of innovative therapies that enhance intestinal adaptation offers potential opportunities, predominantly in developed economies with robust healthcare systems. Emerging markets also present prospects due to improving healthcare infrastructure and government initiatives. Nonetheless, high treatment costs, stringent regulatory frameworks, and the complex nature of SBS act as significant limitations. Challenges such as the need for personalized patient management plans and limited available etiological therapies further complicate market growth. Identifying promising areas of innovation, the development of novel therapeutics focusing on enhancing residual bowel function remains critical. Collaboration between biotech firms and healthcare institutions can drive research into gut microbiome manipulation and biologics development. Moreover, the market's nature, being patient-centric and closely linked with advancements in medical research, necessitates continual engagement with patient advocacy groups and professional bodies to address unmet needs. Businesses can benefit by investing in R&D and adopting patient-centric approaches to tailor treatments, enhance delivery systems, and align with current patient management protocols. This strategic direction will not only tap into existing opportunities but also position businesses effectively in the evolving SBS treatment landscape.

KEY MARKET STATISTICS
Base Year [2023]	USD 818.23 million
Estimated Year [2024]	USD 966.42 million
Forecast Year [2030]	USD 2,788.72 million
CAGR (%)	19.14%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Short Bowel Syndrome Market

The Short Bowel Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increased Prevalence of Short Bowel Syndrome and Awareness Programs
- Rising Efforts in the Launch of Effective Treatments
Market Restraints
- Lack of Approved Treatment Options and Associated Adverse Complications with Drugs
Market Opportunities
- Development of Short Bowel Syndrome Drugs is at a Nascent Stage
- Public-Private Partnerships are Encouraging Pharmaceutical Companies to Develop New Orphan Drugs for Short Bowel Syndrome
Market Challenges
- Limited Initial Diagnostic and Availability of Advanced Option

Porter's Five Forces: A Strategic Tool for Navigating the Short Bowel Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Short Bowel Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Short Bowel Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Short Bowel Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Short Bowel Syndrome Market

A detailed market share analysis in the Short Bowel Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Short Bowel Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Short Bowel Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Short Bowel Syndrome Market

A strategic analysis of the Short Bowel Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Short Bowel Syndrome Market, highlighting leading vendors and their innovative profiles. These include 9 Meters Biopharma, Inc., Adocia SAS, Ardelyx Inc., AstraZeneca PLC, Emmaus Life Sciences, Inc., Merck KGaA, Nestle S.A., Novartis International AG, OPKO Health, Inc., Oxthera AB, Pfizer Inc., PhaseBio Pharmaceuticals Inc., Sancilio and Company, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., VectivBio AG, Viatris Inc., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Short Bowel Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Drug Class, market is studied across GLP-2, Glutamine, and Growth Hormone.
Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Sales, and Retail Pharmacies.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-0309FBC51139

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increased Prevalence of Short Bowel Syndrome and Awareness Programs
  - 5.1.1.2. Rising Efforts in the Launch of Effective Treatments
- 5.1.2. Restraints
  - 5.1.2.1. Lack of Approved Treatment Options and Associated Adverse Complications with Drugs
- 5.1.3. Opportunities
  - 5.1.3.1. Development of Short Bowel Syndrome Drugs is at a Nascent Stage
  - 5.1.3.2. Public-Private Partnerships are Encouraging Pharmaceutical Companies to Develop New Orphan Drugs for Short Bowel Syndrome
- 5.1.4. Challenges
  - 5.1.4.1. Limited Initial Diagnostic and Availability of Advanced Option
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Short Bowel Syndrome Market, by Drug Class

6.1. Introduction
6.2. GLP-2
6.3. Glutamine
6.4. Growth Hormone

7. Short Bowel Syndrome Market, by Distribution Channel

7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Sales
7.4. Retail Pharmacies

8. Americas Short Bowel Syndrome Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Short Bowel Syndrome Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Short Bowel Syndrome Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation

Companies Mentioned

1. 9 Meters Biopharma, Inc.
2. Adocia SAS
3. Ardelyx Inc.
4. AstraZeneca PLC
5. Emmaus Life Sciences, Inc.
6. Merck KGaA
7. Nestle S.A.
8. Novartis International AG
9. OPKO Health, Inc.
10. Oxthera AB
11. Pfizer Inc.
12. PhaseBio Pharmaceuticals Inc.
13. Sancilio and Company, Inc.
14. Swedish Orphan Biovitrum AB
15. Takeda Pharmaceutical Company Limited
16. Teva Pharmaceutical Industries Ltd.
17. VectivBio AG
18. Viatris Inc.
19. Zealand Pharma A/S